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ABSTRACT
Introduction Investigating auditory functions in populations
at risk of developing Alzheimer’s disease (AD) using auditory
neurophysiological measurements can potentially identify
a crucial and sensitive diagnostic window of opportunity in
preclinical AD. Auditory electrophysiological assessments
have gained interest as possible tools for early diagnosis
of AD. This paper outlines the protocol that will be used
to systematically review the published literature currently
available on auditory electrophysiological assessments that
have been used to assess the auditory functions of adults
over the age of 60 years diagnosed with AD or its preclinical
stages.
Methods and analysis All full-length peer-reviewed
publications of original data that use auditory
electrophysiological assessments in AD and its preclinical
stages (subjective cognitive decline (SCD) and mild cognitive
impairment (MCI)) will be considered in this review. The
search will be performed on major electronic databases
(Ovid MEDLINE, Ovid Embase, PsycINFO, PubMed, Scopus
and CINAHL Plus) using keywords alone or in combination
with Medical Subject Headings divided into two domains;
(i) auditory tests and (ii) AD. The database search will
be conducted on the 7th of May 2019. Data analysis will
be completed and reported in the full review. A random
effects meta-analysis will also be conducted using the
Comprehensive Meta-Analysis software, V.3. This review
will describe which auditory electrophysiological tests
have been found to be useful in assessing the auditory
function in cognitively impaired adults (MCI and AD) or
adults with serious complaints about their cognition (SCD).
This review will also identify and describe which auditory
electrophysiological test demonstrates the most sensitivity
in differentiating people at different stages of cognitive
decline.
Ethics and dissemination This systematic review focusses
on analysing already available literature. Therefore, there
will be no requirement for ethical approval. The systematic
review findings will be disseminated through peer-reviewed
publication as well as relevant media platforms, for example,
conferences.
Systematic review registration PROSPERO
CRD42019133553.

Strengths and limitations of this study
►► This systematic review protocol follows the Preferred

Reporting Items for Systematic Review and Meta-
Analysis Protocols (PRISMA-P) guidelines.
►► This protocol outlines the procedure for a systematic
review which will reduce the possibility of duplication of the methods and allows for peer review of
the procedure.
►► This will offer highest level evidence for informed
decisions.
►► The detailed keyword and Medical Subject Headings
term search methods offer a more comprehensive
search of relevant publications.
►► The exclusion of papers that are not published in
English may mean some important additional findings are not taken into consideration.

INTRODUCTION
Worldwide, someone develops dementia
every 3 seconds, and in 2017 the number of
people estimated to be living with dementia
globally was close to 50 million people.1
Without a medical breakthrough the number
of dementia cases is expected to double
every 20 years, with it estimated to be over
152 million cases by 2050.2 Contributing to a
total of 5.4% of deaths in males and 10.6% of
deaths in females each year, dementia is the
second leading cause of death of Australians.3
Everyday approximately 250 Australians are
diagnosed with dementia, and this number is
expected to increase to 650 people a day by
2056.1
Dementia of the Alzheimer’s disease (AD)
type accounts for 60% to 80% of all dementia
cases.4 It is characterised by loss of episodic
memory as well as loss of other cognitive functions.5 Cognitive decline has been shown to be
strongly associated with hearing loss with the
probability of incident dementia log-linearly
increasing with the severity of hearing loss.6
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In addition, results from a number of longitudinal studies
suggest that changes in central auditory processing skills,
even in the absence of severe peripheral hearing loss,
are associated with high incidence of cognitive decline
and AD.7 8 Changes in the human auditory system can
be objectively measured which can provide an avenue in
differentiating normal age-related cognitive dysfunction
from AD and its prodromal states.9–11
Investigating peripheral and central auditory functions
in populations at risk of developing AD using auditory
neurophysiological measurements combined with audiological assessments can potentially identify a crucial and
sensitive diagnostic window of opportunity in preclinical AD. Auditory electrophysiological assessments have
gained interest as possible tools for early diagnosis of AD.
The present paper outlines the protocol used to systematically review the published literature currently available on
auditory electrophysiological assessments that have been
used to assess the auditory functions of adults over the age
of 65 years diagnosed with AD and its preclinical stages
including those with mild cognitive impairment (MCI)
and subjective cognitive decline (SCD). The aims of the
systematic review and meta-analysis are; (i) to determine
the magnitude of auditory electrophysiological component amplitude and/or latency abnormalities present in
AD, MCI and SCD when compared with controls, (ii) to
determine which auditory electrophysiological component can be used to differentiate between the different
study groups (ie, AD, MCI, SCD and controls) and (iii)
to determine which auditory electrophysiological assessments can yield a possible diagnostic tool for preclinical
AD.

METHODS
This systematic review will follow the Preferred Reporting
Items for Systematic Review and Meta-Analysis (PRISMA)
statement.12 This protocol is reported in accordance
with the PRISMA-Protocols (PRISMA-P) 2015 checklist.13
This systematic review is registered in the PROSPERO;
International Prospective Register of Systematic Reviews,
(http://www.crd.york.ac.uk/PROSPERO/).
Eligibility criteria
All full-length peer-reviewed publications of original data
related to auditory electrophysiological assessments in AD
or its preclinical stages available on the selected databases
published between 1985 and May 2019 will be considered
in this review.
The eligibility criteria (table 1) illustrate the inclusion
and exclusion criteria for publications based on four categories; publication type, population type, assessment type
and reported outcome. Only publications of original data
that are reported in English will be included in this review,
publication of non-original data such as reviews or editorials will not be included in this review. In order to be
included in this review all studies must have one or more
subject groups with cognitive impairment associated with
2

AD and its preclinical stages. The studies must also have
used auditory electrophysiological assessments either as a
tool for assessing hearing abilities in cognitively impaired
adults or as a diagnostic tool for cognitive impairment.
human subject pool and subject
Studies using a non-
groups under the age of 60 will be excluded from this
review. The full inclusion and exclusion criteria is illustrated in table 1.
Information sources
The search will be conducted on the following major databases in medicine, neuroscience and psychology: Ovid
Embase, Ovid MEDLINE, PsycINFO, PubMed, Scopus
and CINAHL Plus. A hand search of references and citations of the included publications will also be conducted
using Google Scholar. In addition, a grey literature search
will be conducted using Google Scholar to identify any
relevant studies that would not be found through the
major database searches.
Search strategy
Medical Subject Headings (MeSH) in exploded mode in
conjunction with keyword searches will be used to maximise the sensitivity of the search strategy in the Embase,
MEDLINE and PsycINFO databases. Keyword searches
with synonyms, abbreviations, truncations and different
spellings (see table 2) will also be used in the PubMed,
Scopus and CINAHL Plus databases. The search terms
are divided in two domains; (i) auditory tests and (ii)
Alzheimer’s disease, refer to table 2.
Data management and study selection
All results from database and hand searches will be
exported into EndNote X7 software (Thomson Reuters,
2016), where the duplicate publications will be removed.
The study selection will then be undertaken in two stages;
first, the titles and abstracts will be screened against the
eligibility criteria to confirm whether they are suitable
for the final review; second, the full-texts for the eligible
publications will be analysed against the eligibility criteria.
The search strategy and publication screening will be
conducted by two authors (HYT and DMPJ) assisted by
Covidence,14 a systematic review publication organisational tool (http://www.covidence.org). Any discrepancies between the two authors where a consensus could
not be reached will be resolved through discussion and
consultation with a third reviewer (WHAMM).
Data items and collection process
Data extracted from publications for this review will
include the following:
1. Publication characteristics: authors, year of publication, journal of publication, title, study objective, study
design.
2. Participant characteristics: geographical location of the
study, number of participants, age of subject groups,
diagnosis method of the disease (SCD or MCI or AD),
Mini-Mental State Examination score (if reported).
Tarawneh HY, et al. BMJ Open 2020;10:e033308. doi:10.1136/bmjopen-2019-033308
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Table 1 Eligibility criteria
Eligibility criteria

Include

Exclude

Publication type

►► Peer-reviewed, full-length publications of original data.

►► Non-original data publications; editorials,

►► Publications written in English.

►► Publications in any language other than

reviews, letters, opinion pieces,
miscellaneous reports, non-empirical
studies.
English.

►► All articles on the topic published between 1985 and May

2019.

Population type

►► Studies that include participants with dementia of the

Alzheimer’s type and/or its prodromal states.

►► Studies that only address non-cognitively

impaired adults or adults without memory
complaints.

►► Studies with participants that are healthy and participants with ►► Studies with no age matched comparison

cognitive impairment or memory complaints if the data for
cognitively impaired participants is reported.

►► Studies conducted on humans only.

(control) group.

►► Studies on children or adults with the mean

age under 60.

►► Studies conducted on humans and other animals if data for

humans is reported.

►► Studies with an age matched comparison (control) group.
►► Studies on elderly adult participants; mean age of 60 years

old or older (If mean age not specified the age range for the
subject must start at 60 years old).

Assessment type

►► Studies that use auditory electrophysiological assessments

►► Studies that only use auditory assessments

►► Studies that use a recognised diagnostic criteria,

►► Non-human studies.

either as a tool for assessing hearing abilities in cognitively
impaired adults or as a diagnostic tool for cognitive
impairment.
neuropsychological evaluation or medical imaging to
diagnose/classify the AD or MCI groups.

that are not electrophysiological.

►► Studies that use non-auditory electrophysiological

assessments as well as auditory electrophysiological
assessments, if the data for the auditory electrophysiological
assessments is reported.

Reported outcome ►► Latency and amplitude measures of the auditory
electrophysiological assessments.

►► Self-reported outcomes.

AD, Alzheimer’s disease; MCI, mild cognitive impairment.

3. Assessment characteristics: testing methods applied,
for example, auditory electrophysiology assessment
task/paradigm.
4. Outcome characteristics: which auditory electrophysiological measures were used, major findings on components latency and/or amplitude, major conclusions
and limitations or difficulties of testing procedures.
The data extracted will be analysed qualitatively to
identify any particular patterns, similarities or differences
between studies. The data extracted from the publications will provide information about any gaps in knowledge and the future direction of research on auditory
electrophysiology in AD and its preclinical stages.
Quality assessment
All articles will be assessed to address the risk of; selection bias, performance bias, analysis bias and reporting
bias. A quality assessment tool developed by Thomas et
Tarawneh HY, et al. BMJ Open 2020;10:e033308. doi:10.1136/bmjopen-2019-033308

al15 will be used to evaluate the methodological quality of
the quantitative studies included in the systematic review.
The quality assessment findings will be analysed, and the
evidence will be tabulated in order to grade the recommendations based on the American Society of Plastic
Surgeons’ Evidence Rating Scale for Therapeutic Studies
scale for grading recommendations.
Meta-analytic approach
The meta-analysis will be conducted using the Comprehensive Meta-
Analysis (V.3) software developed by
Biostat.16 The data in each study will be refined for the
meta-analysis; (1) grand averages of multiple electrode
site measures will be pooled into a single mean for each
group, (2) measures reported in subgroups (eg, male
and female separately) will be pooled and analysed as a
single group, (3) event-related potential (ERP) components reported as subcomponents (eg, P300 as P3a and
3
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Table 2 Keywords and Medical Subject Headings (MeSH) terms (explode) applied per domain in search databases
Domain

Keywords

MeSH terms

Auditory tests

psychoacoustic test* OR auditory test OR central auditory test
OR electrophysiological assessment OR electrophysiology OR
electroencephalography OR ECochG OR ECOG OR event related
potential OR ERP OR AEP OR evoked auditory response OR acoustic*
evoked response OR acoustic* evoked potential OR auditory event
related potential OR AERP OR auditory brainstem response OR ABR
OR auditory brainstem responses OR ABRs OR speech-evoked ABR
OR complex ABR OR cABR OR brainstem auditory evoked potential
OR frequency following response OR FFR OR frequency following
potential OR FFP OR envelope following response OR EFR OR auditory
middle latency response OR AMLR OR auditory MLR OR middle latency
response OR middle-latency response OR MLR OR middle latency
responses OR MLRs OR transient middle latency response OR middle
latency auditory evoked potentials OR MLPs OR Na OR Pa OR Nb
OR Pb OR slow vertex potential OR slow-vertex potential OR SVP OR
slow vertex response OR SVR OR V potential OR late cortical response
OR long latency auditory evoked potential OR cortical event-related
potentials OR P1 OR P100 OR N1 OR N100 OR P2 OR P200 OR N2
OR N200 OR P50 OR late positive component OR late positive complex
OR LPC OR late latency response OR LLR OR slow latency auditory
evoked potentials OR SLAEPs OR late latency auditory evoked potentials
OR LLAEPs OR P300 OR P3 OR mismatched negativity OR MMN OR
mismatched field OR MMF OR contingent negative variation OR CNV
OR N4 OR N400 OR P6 OR P600 OR auditory steady-state response
OR ASSR OR multiple auditory steady-state response OR MASTER OR
multiple-frequency ASSR OR multiple-ASSR OR steady state evoked
response OR SSER OR Steady state evoked potential OR SSEP OR
4 kHz response
Alzheimer* disease OR Alzheimer* OR Dementia OR AD OR cognitive
impairment OR cognitive decline OR cognitive processing OR cognitive
ability dementia OR Alzheimer* type dementia OR mild cognitive
impairment OR MCI OR amnestic MCI OR amnestic mild cognitive
impairment OR minimal cognitive impairment OR moderate cognitive
impairment OR severe cognitive impairment OR subjective memory
complainers OR SMC OR subjective cognitive decline OR SCD

Hearing tests OR Auditory evoked
potentials OR Audiometry

Alzheimer’s disease

P3b) will be combined as a single mean for each group
and (4) only baseline measures of the ERP components
will be included in the meta-analysis. Standard difference
in mean with 95% CIs will be reported as synthesised
measure of effect size. The standard mean difference
reflects the difference between the means of two groups
divided by their pooled SD. The data for the meta-analysis
will be entered as continuous outcomes under the random
effects model. The random effects model will be used to
account for variation between study methodologies. The
q-value statistic will be performed to test heterogeneity of
the studies and the I² statistic will indicate heterogeneity
as a percentage. A p value <0.05 will be considered statistically significant for all analyses.
Synthesis of results
The data extracted from the studies will be tabulated to
illustrate the overall methodological quality, the main
findings, the main conclusions and the level of evidence
for each study. The findings will be analysed based on
the patient group (SCD, MCI or AD) and the clinical
testing approach (type of auditory electrophysiological
assessment and type of outcome measures) in order to
4

Dementia OR Cognitive
dysfunction, impairment OR
Cognition disorders

synthesise the evidence. An understanding of the feasibility, efficiency, effectiveness and quality of the use of
each auditory electrophysiological assessment in the
patient groups will be developed through the synthesis
of the results.
Patient and public involvement
Patient and public involvement is not required for this
systematic review.
ETHICS AND DISSEMINATION
The aim of this review is to investigate and describe the
different auditory electrophysiological tests that have
been used in clinical studies in participants with SCD,
MCI and AD. This review will provide information about
which auditory electrophysiological tests have been found
to be useful in assessing auditory function in cognitively
impaired adults. Additionally, the review will identify the
strengths and limitations of each auditory electrophysiological test and identify which auditory electrophysiological test demonstrates most sensitivity in differentiating
subject groups; that is, between those at different stages
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of cognitive impairment. This review will also contribute
to the study design of clinical studies looking at auditory
evoked potentials in patients with AD and its preclinical
stages. The full review and meta-analysis will be submitted
for publication in a peer-reviewed journal and the results
will be presented at conferences and meetings relevant to
the field. Ethical approval is not required as no primary
data will be collected.
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